Xavant Technology set to Disrupt Neuropathic Pain Treatment in the UK
Trial study at St Thomas’s Pain Management Centre shows dramatic effectiveness to treat chronic intractable pain PRETORIA, South Africa, 27 March, 2018 – Xavant Technology (Pty) Ltd today announced the launch of their Stimpod NMS460 in the U.K. The Stimpod NMS460, a non-invasive neuromodulation device, is focused on the symptomatic relief and management of neuropathic pain as well as an adjunctive treatment in the management of post-surgical pain, post-traumatic acute pain problems, and an adjunct…
Source: RealWire